High Expression of Hypoxia Inducible Factor 1α Related with Acquired Resistant to EGFR Tyrosine Kinase Inhibitors in NSCLC

Overview

Journal Sci Rep

Specialty Science

Date 2021 Jan 14

PMID 33441708

Citations 7

Authors

Qian Jin

Feihua Huang

Xianrong Xu

Haidong He

Yingqing Zhang

Affiliations

Soon will be listed here.

Abstract

The acquired resistance of the first generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is a main factor leading to poor prognosis of non-small cell lung cancer (NSCLC), so we researched whether the high expression of hypoxia-inducible factor-1α (HIF-1α) in EGFR-TKIs sensitive NSCLC tissue tends to induce the acquired resistance. We detected the HIF-1α in normal lung tissue, EGFR-TKIs sensitive NSCLC tissue, the first generation EGFR-TKIs acquired resistant NSCLC tissue and acquired EGFR T790M mutation NSCLC tissue with the method of immunohistochemistry. Then, we compared the expression of HIF-1α in these tissues, and evaluate the effect of HIF-1α expression to the occurrence of acquired resistance. The expression of HIF-1α was much higher in the EGFR-TKIs sensitive NSCLC tissue than that in normal lung tissue. HIF-1α level became higher after the occurrence acquired resistance. There was negative correlation between HIF-1α level before receiving treatment and the time of acquired resistance occurring as well as the acquired EGFR T790M mutation occurring. As the treatment going on, EGFR-TKIs sensitivity rate of low HIF-1α level group was much higher than that of high level group. The high expression of HIF-1α related with the acquired resistance of the first generation EGFR-TKIs, and HIF-1α can be a biomarker to predict the early occurrence of acquired resistance.

Citing Articles

Uncovering the therapeutic efficacy and mechanisms of Quercetin on traumatic brain injury animals: a meta-analysis and network pharmacology analysis.

Cai Y, Zhang X, Qian H, Huang G, Yan T Metab Brain Dis. 2024; 40(1):13.

PMID: 39556146 DOI: 10.1007/s11011-024-01449-x.

EGFR-Tyrosine Kinase Inhibitors Induced Activation of the Autocrine CXCL10/CXCR3 Pathway through Crosstalk between the Tumor and the Microenvironment in EGFR-Mutant Lung Cancer.

Hong S, Kang N, Kim O, Hong S, Park J, Kim J Cancers (Basel). 2023; 15(1).

PMID: 36612121 PMC: 9817815. DOI: 10.3390/cancers15010124.

New horizons in modulating the radio-sensitivity of head and neck cancer - 100 years after Warburg' effect discovery.

Mirestean C, Iancu R, Iancu D Front Oncol. 2022; 12:908695.

PMID: 36568220 PMC: 9780029. DOI: 10.3389/fonc.2022.908695.

Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer.

Nishihara S, Yamaoka T, Ishikawa F, Higuchi K, Hasebe Y, Manabe R Genes (Basel). 2022; 13(12).

PMID: 36553449 PMC: 9778480. DOI: 10.3390/genes13122183.

Amphiregulin/epidermal growth factor receptor/hypoxia-inducible factor-1α pathway regulates T helper 9 and T cytotoxic 9 cell response in adult patients with infectious mononucleosis.

Li Y, Li L, Zhang W, Gao Y Biomol Biomed. 2022; 23(1):63-72.

PMID: 36154925 PMC: 9901907. DOI: 10.17305/bjbms.2022.8013.

References

Zhang K, Yuan Q . Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer. J Cancer Res Ther. 2017; 12(Supplement):C131-C137. DOI: 10.4103/0973-1482.200613. View

Wilson W, Hay M . Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011; 11(6):393-410. DOI: 10.1038/nrc3064. View

Wigerup C, Pahlman S, Bexell D . Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharmacol Ther. 2016; 164:152-69. DOI: 10.1016/j.pharmthera.2016.04.009. View

Warfel N, El-Deiry W . HIF-1 signaling in drug resistance to chemotherapy. Curr Med Chem. 2014; 21(26):3021-8. DOI: 10.2174/0929867321666140414101056. View

Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio P . Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003; 3(4):347-61. DOI: 10.1016/s1535-6108(03)00085-0. View

Burroughs S, Kaluz S, Wang D, Wang K, Van Meir E, Wang B . Hypoxia inducible factor pathway inhibitors as anticancer therapeutics. Future Med Chem. 2013; 5(5):553-72. PMC: 3871878. DOI: 10.4155/fmc.13.17. View

Ellis L, Hicklin D . Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology. Clin Cancer Res. 2009; 15(24):7471-7478. DOI: 10.1158/1078-0432.CCR-09-1070. View

Messai Y, Gad S, Noman M, Le Teuff G, Couve S, Janji B . Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status. Eur Urol. 2015; 70(4):623-632. DOI: 10.1016/j.eururo.2015.11.029. View

Ruf M, Moch H, Schraml P . PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma. Int J Cancer. 2016; 139(2):396-403. DOI: 10.1002/ijc.30077. View

10.

Noman M, Janji B, Hu S, Wu J, Martelli F, Bronte V . Tumor-Promoting Effects of Myeloid-Derived Suppressor Cells Are Potentiated by Hypoxia-Induced Expression of miR-210. Cancer Res. 2015; 75(18):3771-87. DOI: 10.1158/0008-5472.CAN-15-0405. View

11.

Rustum Y, Chintala S, Durrani F, Bhattacharya A . Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy. Int J Mol Sci. 2018; 19(11). PMC: 6275006. DOI: 10.3390/ijms19113378. View

12.

Lin H, Jiang X, Zhu H, Jiang W, Dong X, Qiao H . 2ME2 inhibits the activated hypoxia-inducible pathways by cabozantinib and enhances its efficacy against medullary thyroid carcinoma. Tumour Biol. 2015; 37(1):381-91. DOI: 10.1007/s13277-015-3816-1. View

13.

Conley S, Baker T, Burnett J, Theisen R, Lazarus D, Peters C . CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer. Breast Cancer Res Treat. 2015; 150(3):559-67. DOI: 10.1007/s10549-015-3349-8. View

14.

Aghazadeh S, Yazdanparast R . Activation of STAT3/HIF-1α/Hes-1 axis promotes trastuzumab resistance in HER2-overexpressing breast cancer cells via down-regulation of PTEN. Biochim Biophys Acta Gen Subj. 2017; 1861(8):1970-1980. DOI: 10.1016/j.bbagen.2017.05.009. View

15.

Morgillo F, Cascone T, DAiuto E, Martinelli E, Troiani T, Saintigny P . Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors. Br J Cancer. 2011; 105(3):382-92. PMC: 3172903. DOI: 10.1038/bjc.2011.244. View

16.

Lu Y, Liang K, Li X, Fan Z . Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha. Mol Cancer. 2007; 6:63. PMC: 2117021. DOI: 10.1186/1476-4598-6-63. View

17.

Allon I, Kaplan I, Allon D, Vered H, Shlomi B, Hirshberg A . HIF-1α, VEGF, and EGFR: contributing factors in the pathogenesis of necrotizing sialometaplasia. Oral Dis. 2013; 20(5):440-5. DOI: 10.1111/odi.12149. View

18.

Cao W, Kawai N, Miyake K, Zhang X, Fei Z, Tamiya T . Relationship of 14-3-3zeta (ζ), HIF-1α, and VEGF expression in human brain gliomas. Brain Tumor Pathol. 2013; 31(1):1-10. DOI: 10.1007/s10014-013-0135-3. View

19.

Huang J, Wang Y, Zhai Y, Wang J . Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report. Thorac Cancer. 2018; 9(6):745-749. PMC: 5983145. DOI: 10.1111/1759-7714.12637. View

20.

Kozlov V, Karpov I, Kovalenko S, Shamanin V . Adenocarcinoma of the lung with rare insertion mutation in EGFR exon 19 that had partial response to gefitinib: a case report. Exp Oncol. 2018; 39(2):155-156. View